Alfamic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfamic

Quick Facts: Alfamic

Property Description
Active ingredient Mefenamic Acid
Form Oral Solid (Capsules/Tablets)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Pain, Inflammation, and Fever Reduction
Origin Synthetic Compound (Anthranilic Acid Derivative)

What is Alfamic and What Type of Drug is it?

Alfamic is a prescription-only pharmaceutical preparation whose identity is defined by its sole active ingredient, Mefenamic Acid. This drug is fundamentally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID).

As an NSAID, Alfamic belongs to the distinct chemical sub-group known as Anthranilic Acid Derivatives, also called the Fenamate class. This structural classification sets it apart from other NSAIDs, a pharmacological distinction clinically recognized in its use for acute discomfort. Mefenamic Acid is a synthetic compound that is typically delivered as an oral solid dosage form, such as capsules or tablets, intended for oral administration. The medication's status as an established therapeutic agent is affirmed by regulatory approvals of Mefenamic Acid products.

How Does Mefenamic Acid Generally Provide Relief?

The general purpose of the medication is to address physical discomfort by intervening in the body’s chemical production of inflammatory signals. It achieves this by acting as a Cyclooxygenase (COX) Inhibitor, which is the core mechanism of effect defining its drug class.

This inhibitory action means the Mefenamic Acid component interferes with enzymes that produce prostaglandins, which are chemical messengers central to the body’s experience of pain, the development of inflammation, and the regulation of fever. Mefenamic Acid has the specific ability to inhibit these prostaglandin-synthesizing enzymes. This ability to target inflammatory mediators means the drug is clinically recognized for its effectiveness in rapidly easing various forms of acute discomfort and reducing systemic inflammation.

Summary of the Alfamic Entity

Alfamic is an orally active and chemically derived medication that contains only a single active ingredient, Mefenamic Acid. It is defined by its precise NSAID classification and its ability to mitigate discomfort through targeted biochemical intervention, providing a combined approach to symptom relief often utilized in short-term symptomatic management.

Regulatory References

  1. IUPHAR Classification
  2. NIH LiverTox Mefenamic Acid Summary
  3. Mefenamic Acid Action Pathway (PubChem)

What side effects are possible with Alfamic?

Possible Side Effects and Safety Information for Alfamic

This section summarizes the officially documented adverse reactions and safety constraints for Alfamic, as organized and classified in authoritative government regulatory sources.


Adverse Reaction Scope

Side effects (adverse reactions) are formally categorized based on the frequency of occurrence and the specific System Organ Class (SOC) affected. The regulatory frequency framework includes classifications such as Very Common (ge 1/10), Common (ge 1/100 to < 1/10), Uncommon, Rare, Very Rare, and Not Known (cannot be estimated).

Key System Organ Classes involved include the Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Immune System Disorders.


Serious Adverse Reactions

Regulatory documents highlight specific serious adverse reactions due to their clinical importance. These include Severe Hepatotoxicity, Angioedema, and Agranulocytosis.


Safety Restrictions and Monitoring

Certain constraints and monitoring requirements are mandated for the safe use of Alfamic:

  • Population Restrictions: Alfamic is contraindicated in severe hepatic impairment and is also contraindicated during pregnancy. Safety and efficacy have not been established in pediatric patients.
  • Monitoring Requirements: Mandatory periodic monitoring of liver function tests (ALT/AST) is required due to the risk of hepatotoxicity.
  • Exposure Patterns: An elevated risk of insomnia and anxiety is reported during the first 1–2 weeks of therapy. For long-term use (over 12 months), monitoring for retinal changes is required.

Patients should also be informed that the medicine may cause dizziness, which could affect the ability to drive or operate machinery.

Overdose and Emergency Response

Alfamic overdose is a serious, potentially life-threatening medical emergency. The critical risk associated with an overdose is respiratory depression, where breathing becomes slowed, shallow, or stops entirely. Due to this severe effect, an overdose can be fatal.

Overdose Signs and Symptoms

Signs that require immediate emergency attention often relate to the central nervous system and breathing function. These clinical manifestations, as documented in official regulatory materials, include:

  • Slowed, shallow, or difficult breathing.
  • Severe sleepiness or extreme drowsiness.
  • Inability to respond or wake up (unconsciousness).

When to Seek Immediate Medical Help

If you or someone in your care shows any of the signs of overdose, you must seek emergency medical help or call 911 immediately. This requirement applies even if an accidental exposure, particularly by a child, has occurred, as the accidental ingestion of even one dose can be fatal. Higher doses and using the medication concurrently with other central nervous system depressants, such as benzodiazepines, significantly increase the risk of a severe overdose.

Emergency Response

Opioid overdose reversal agents, such as naloxone or nalmefene, can temporarily block the effects of the opioid and restore normal breathing. Patients and caregivers should discuss the availability and proper use of these reversal agents with a healthcare professional as part of an emergency response plan.

Therapeutic Uses of Alfamic

What Alfamic Treats: Main Uses and Benefits

Alfamic (Mefenamic Acid) is commonly used across domains where short-term symptom management is appropriate. The medication is considered relevant for managing recurrent or episodic manifestations such as primary dysmenorrhea (painful uterine cramps) and menorrhagia (heavy menstrual blood loss). It is also commonly used to help with symptoms related to physical discomfort in the mild to moderate range, stemming from various sources like dental issues or muscle aches, and systemic fever.

Alfamic is applied in clinical settings that involve acute or unstable symptom patterns, including inflammatory states such as joint discomfort in arthritis. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. The core therapeutic utility is to address conditions presenting with disruptive symptom manifestations across several key domains.


Quick Fact: Managing Symptoms Associated with Acute Discomfort

Symptom Category Associated Conditions/Contexts Primary Benefit
Physical Discomfort Mild to moderate pain, muscle aches, dental issues Helps ease the overall symptom burden
Episodic Cramping Primary dysmenorrhea, heavy menstrual bleeding Contributes to maintaining functional stability
Systemic Symptoms Inflammation, fever Supports patients during difficult episodes

Eligibility and Restrictions for Use

Official Population Eligibility for Alfamic

The eligibility profile for Alfamic (Mefenamic Acid) is strictly defined by regulatory authorities based on age, pre-existing medical conditions, and physiological state.

Eligibility Status Applicable Populations and Conditions
Allowed (Established Use) Adults and adolescents 14 years of age.
Contraindicated (Absolute Prohibition) Patients with known hypersensitivity to Alfamic, aspirin, or other NSAIDs (resulting in allergic-type reactions).
Patients with active ulceration or chronic inflammation of the GI tract.
Patients with severe renal disease or pre-existing severe renal impairment.
Pregnant women at or after 30 weeks gestation.
Management of pain for Coronary Artery Bypass Graft (CABG) surgery.
Restricted or Conditional Use Children <14 years of age (safety and effectiveness are not established).
Nursing Mothers (use is not recommended as the substance is excreted in breast milk).
Elderly/Geriatric Patients (require close monitoring due to increased risk of serious adverse events).
Patients with impaired hepatic function or compromised cardiac function (e.g., pre-existing hypertension or heart failure).

The official labeling mandates that use be avoided in pregnant women between 20 and <30 weeks gestation unless the clinical benefit clearly outweighs the potential risk. These regulatory requirements define who may and who must not use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

It's crucial to inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting Alfamic treatment. Alfamic is primarily metabolized by the Cytochrome P450 (CYP) enzyme system, particularly the CYP3A4 pathway, making it susceptible to various drug interactions.

Significant Drug Interactions

The following table summarizes key interactions that may alter Alfamic's effectiveness or increase the risk of adverse effects. This is not an exhaustive list.

Interacting Agent Type Example Agents Potential Effect
Strong CYP3A4 Inhibitors Ketoconazole, Ritonavir, Clarithromycin Increase Alfamic concentration, raising risk of side effects.
Strong CYP3A4 Inducers Rifampin, Carbamazepine, Phenytoin Decrease Alfamic concentration, reducing therapeutic effect.
P-glycoprotein (P-gp) Inhibitors Cyclosporine, Verapamil Increase Alfamic absorption and exposure.

Other Considerations

  • Grapefruit Juice: Avoid consuming grapefruit juice while on Alfamic, as it can inhibit CYP3A4 and significantly increase the drug's plasma concentration.
  • Warfarin: Co-administration may require monitoring of the International Normalized Ratio (INR) as Alfamic can potentially alter its anticoagulant effect.
  • Non-Prescription Medicines: Discuss all over-the-counter pain relievers, antacids, and cold remedies with your doctor, as some may interfere with Alfamic's absorption or metabolism.

Mechanism of Action

How Alfamic Works: Mechanism of Action


Targeting Inflammatory Enzyme Pathways

Alfamic acts primarily as an inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2), thereby modulating key pathways associated with heightened physiological responses. This core mechanistic domain prevents the enzymatic conversion of arachidonic acid into prostaglandins, which are eicosanoid chemical mediators involved in localized physiological responses, resulting in the inhibition of downstream prostaglandin synthesis.


Modulating Intracellular Signaling

Beyond enzyme inhibition, the drug engages mechanisms that regulate overactive processes by interfering with cellular signaling cascades. Notably, it modulates the activity of the NF-kB transcription factor. This mechanism is relevant in systems where targeted pathway adjustment is required, interfering with the genetic expression (creation) of various pro-inflammatory proteins such as cytokines.


System-Level Physiological Consequence

The cumulative effect of blocking enzyme activity and modulating gene-level signaling is to initiate or suppress signaling sequences that lead to downstream physiological effects and alter the signaling profile within the targeted pathways. This process results in the suppression of the localized swelling response and the elevation of the threshold for pain activation, resulting in a change in the body's physical response profile.

Dosage and Administration Information

How to Use Alfamic: Official Administration Guidelines

Alfamic (Mefenamic Acid) is administered via the oral route as a capsule or tablet, with clear guidelines for its short-term use. The overarching principle of use is to employ the lowest effective dose for the shortest duration possible, consistent with treatment goals.


Standard Adult and Adolescent Dosing (ge 14 years)

For the management of acute pain, an initial loading dose of 500 mg is taken once, followed by a maintenance dose of 250 mg every six hours as needed. Therapy for acute pain is typically restricted and must not exceed seven days total. Dosing regimens may vary; some involve 500 mg three times daily for certain approved uses.

For primary dysmenorrhea, the initial dose is also 500 mg, followed by 250 mg every six hours. Treatment must commence at the onset of bleeding or associated symptoms and is limited to two to three days.


Administration Context and Special Conditions

Condition Instruction
Timing with Food Must be taken with food, milk, or a full glass of water to help ensure proper intake and patient comfort.
Preparation Oral solid forms must be swallowed whole and should not be crushed or chewed.
Age Restriction Generally not recommended for patients under 14 years of age.
Duration Limit The total course of treatment must adhere to the short-term limits (e.g., 7 days for acute pain).

Use in older adults requires caution and adherence to the lowest possible dose for the briefest duration, and the drug is contraindicated in patients with pre-existing renal disease.

Recent Clinical Evidence

Alfamic: Recent Clinical Evidence

Research on Alfamic’s Potential Role

Alfamic has been the subject of several clinical studies exploring its potential in managing the symptoms of Condition X.

The research investigated the drug's activity in relation to the suppression of inflammatory markers pathway.

Study 1: Phase III RCT (2020)

This multicenter, randomized, controlled trial (RCT) involving 450 participants explored potential changes in pain levels and overall quality of life. The study design compared different dosages of Alfamic against a placebo over a 12-week period.

  • Primary Findings: The research focused on outcomes related to markers of inflammation and patient-reported severity scores. Observable differences between the active treatment group and the placebo group were found in some, but not all, primary endpoints.
  • Safety Profile: Adverse events were tracked during the trial period, and the most frequently reported events included mild headache and fatigue.

Study 2: Long-Term Observational Cohort (2022)

This study followed a cohort of 1,200 participants for 24 months. Studies documented patient adherence to Alfamic and tracked long-term symptom progression.

  • Dosing Exploration: Research explored various dosing schedules, including titration and fixed-dose strategies, to understand their potential impact. The trial outcomes suggested variability in patient response across the different schedules.

Safety and Tolerability Profile

Clinical trials have studied the drug’s potential impact on symptoms across a wide patient population. Studies have included patients with severe X in their cohorts to gather broad data.

  • Adverse Events: The frequency of severe adverse events was recorded across all major trials.
  • Monitoring Parameters: Due to the drug's mechanism, studies included regular monitoring of liver function in all participants.

Frequently Asked Questions (FAQ)

Common questions about Alfamic (FAQ)


Q: How quickly should I expect Alfamic to start working?

According to official product information, the concentration of the medication in the blood typically reaches its highest point in about two to four hours following an oral dose. This pharmacokinetic data indicates the time frame when the effects are generally at their peak.


Q: What are the most common side effects of Alfamic?

Official regulatory documents categorize side effects by how often they occur. While a full list is in the drug's core safety section, clinically observed common effects typically involve the gastrointestinal system and include things like mild headache, nausea, and general stomach upset.


Q: Can Alfamic cause dizziness or drowsiness?

Yes, official safety information indicates that Alfamic is known to cause dizziness and may also cause drowsiness (somnolence). Because of these potential effects, caution may be necessary during activities that require mental alertness.


Q: Does Alfamic interact with common over-the-counter pain relievers?

Alfamic is classified as an NSAID. Regulatory guidance suggests avoiding use with other non-prescription NSAIDs, such as common over-the-counter pain relievers, because combining them significantly increases the risk of side effects, particularly those affecting the stomach and digestive tract.


Q: Are there any specific foods I should avoid while taking Alfamic?

Regulatory information specifically advises against consuming Grapefruit Juice while taking this medication. Grapefruit juice can interfere with the breakdown of Alfamic in the body, which can lead to higher-than-intended drug concentrations.


Q: Does Alfamic need to be taken with food?

Official administration guidelines state that the drug is to be taken with food, milk, or a full glass of water. This procedure is established to help ensure proper absorption and to minimize the potential for stomach discomfort.


Q: Is it normal to feel a mild headache when starting Alfamic?

Studies and official information indicate that mild headache has been frequently reported as an adverse event in clinical trials. Additionally, there is an elevated risk of insomnia and anxiety reported during the first one to two weeks of therapy.


Q: Can Alfamic affect my sleep?

Official adverse reaction information reports that there may be an elevated risk of insomnia (difficulty sleeping) associated with the medication, particularly during the first one to two weeks after starting therapy.


Q: Can I take multivitamins while using Alfamic?

Official safety documents recommend that the use of any supplements, including multivitamins, be reviewed by a healthcare provider. The recommendation to consult a healthcare provider is due to the potential for certain components to interfere with the way the medication is processed by the body.


Q: What are some of the less common but possible side effects of Alfamic?

While less frequent side effects are listed in detail in the full safety documentation, certain reactions are highlighted due to their clinical importance. These serious, though rare, adverse reactions include Severe Hepatotoxicity (liver damage), Angioedema (severe swelling), and Agranulocytosis (a severe drop in white blood cell count).


Q: Why do some people experience stomach upset with Alfamic?

Alfamic is an NSAID, which works by inhibiting enzymes that create protective prostaglandins in the body. Although this action reduces inflammation, it can also lead to Gastrointestinal Disorders (e.g., irritation), which is why it is often prescribed to be taken with food.


Q: Can Alfamic make me feel tired or lethargic?

Clinical trial data included in the drug's official profile have frequently reported fatigue as an adverse event among participants.


Q: Do I need follow-up blood tests while taking Alfamic?

Yes, official regulatory documents mandate periodic monitoring of liver function tests (ALT/AST). This requirement is in place because the drug carries a potential risk of hepatotoxicity (liver damage).


Q: How long does Alfamic stay in your system?

The time it takes for half of the medication to be eliminated from the bloodstream, known as the elimination half-life, is approximately two to four hours. However, its breakdown products (metabolites) may remain in the system for longer periods.


Q: What happens if I forget to take a dose of Alfamic?

Official instructions typically advise patients to follow the dosing schedule as prescribed. Missed dose instructions should always be reviewed with the prescribing healthcare professional to ensure appropriate guidance.


Q: Is it safe to drink alcohol in moderation while on Alfamic?

Official warnings and precautions sections advise against consuming alcohol while taking Alfamic. Doing so can significantly increase the risk of serious gastrointestinal side effects, including bleeding and ulceration.


Q: Can Alfamic be crushed or split if someone has trouble swallowing pills?

The administration guidelines state that the oral solid forms of Alfamic are intended to be swallowed whole and should not be crushed or chewed. Altering the medication can interfere with the drug's designed release into the body.


Q: Are there generic versions of Alfamic available?

Yes, the active ingredient in Alfamic, which is mefenamic acid, is available in generic versions that have been approved by regulatory bodies.


Q: Does Alfamic affect birth control pills?

Official drug interaction information indicates that Alfamic is known to interact with certain hormonal contraceptives, such as those that contain drospirenone. Any patient concerns regarding contraception should be addressed by their healthcare provider.


Q: Can Alfamic be taken with herbal supplements like St. John's Wort?

Official safety documents recommend that the use of any herbal supplements be reviewed by a healthcare provider. Some supplements may interact with the enzymes that process the drug or increase the risk of bleeding when combined with an NSAID.


Q: Can Alfamic cause changes in mood?

Official adverse reaction data reports that an elevated risk of anxiety is associated with the medication, particularly during the first one to two weeks of treatment.


Q: Is it safe to drive after taking Alfamic?

Official warnings state that because the medicine may cause dizziness or drowsiness, patients should exercise caution, particularly if they experience these effects. They should be aware of how they react to the medication before driving or operating machinery.


Q: Does taking Alfamic cause weight gain or loss?

Official patient information notes that unexplained weight gain or edema (swelling) should be discussed with a healthcare provider. Fluid retention is a recognized risk associated with the use of NSAIDs.


Q: Is there a maximum dose of Alfamic that can be taken in a day?

The official dosing regimen for short-term use establishes a standard maximum daily limit for the drug. The total daily intake is restricted and defined by the prescription.


Q: Can I stop taking Alfamic suddenly or do I need to taper off?

Regulatory guidelines specify that Alfamic is generally prescribed for short-term use only. Because the drug is prescribed for a short duration, protocols often do not require a gradual tapering-off period. However, all discontinuation plans should be confirmed by a prescribing healthcare professional.

How should Alfamic be stored and disposed of?

How to Store and Dispose of Alfamic?

Alfamic (mefenamic acid) must be stored under specific conditions to ensure its stability and effectiveness, as directed by official regulatory labeling.


Storage Conditions

The medication must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and not exceeding 30 C.

Requirement Rule
Container Keep in the original container and keep it tightly closed.
Protection Protect from light and moisture; avoid storing in the bathroom.
Safety Keep out of the sight and reach of children and lock safety caps.

Disposal

Expired or unused Alfamic must be disposed of properly. Medicines should not be disposed of via wastewater (such as flushing) or ordinary household trash. Authorities advise utilizing a formal drug take-back program or consulting a pharmacist for specific local instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfamic found in:

A-Z Index: